This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IL-35 Antagonist (Tizona)

Tizona Therapeutics, Inc.

Drug Names(s): IL-35 Antagonist

Description: Tizona's IL-35 antagonist is a proprietary compound that targets IL-35. IL-35 is an immunosuppressive cytokine, predominantly expressed by Tregs. IL-35 is involved in suppression of anti-tumor immunity through its modulation of effector T cells, as well as myeloid cells. Blocking IL-35’s activity may reverse immune suppression in the tumor microenvironment and lead to a robust and effective anti-tumor immune response.

IL-35 Antagonist (Tizona) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug